Low INPP4B expression predicts poor prognosis locally advanced and metastatic bladder cancer
BAUS ePoster online library. Wei Shen T. 06/30/16; 132018; P11-3 Disclosure(s): none to disclose
Mr. Tan Wei Shen
Mr. Tan Wei Shen
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
P11-3

INTRODUCTION

Traditional prognostic markers such as tumour grade and stage have a limited role in predicting outcomes in bladder cancer (BCa). Inositol polyphosphate-4-phosphatase, type II (INPP4B) is a tumour suppressor gene, and loss of INPP4B is associated with a poor prognosis in prostate and breast cancer with limited evidence in BCa.

PATIENT & METHODS

A tissue microarray (TMA) of 105 patients with stage IV (pT4b or N1/2) or metastatic BCa who had stable disease after chemotherapy was stained for INPP4B. All patients did not have radical treatment. Light microscopy was used to examine TMA cores. Primary end point was overall survival (OS).

RESULTS

Median follow-up was 17.4 months (range: 1.4-45.5, IQR: 7.1-20.1). INPP4B was positive in 56 patients (66.7%) while 28 patients (33.3%) had low/ negative INPP4B expression. INPP4B negative patients were significantly associated with shorter OS (HR: 1.97, 95% CI: 1.09- 3.57; p=0.022).

CONCLUSION

Loss of INPP4B was associated with shorter OS in BCa patients with stage IV or metastatic disease. Further work is needed to determine if INPP4B is a prognostic marker for response to chemotherapy.

P11-3

INTRODUCTION

Traditional prognostic markers such as tumour grade and stage have a limited role in predicting outcomes in bladder cancer (BCa). Inositol polyphosphate-4-phosphatase, type II (INPP4B) is a tumour suppressor gene, and loss of INPP4B is associated with a poor prognosis in prostate and breast cancer with limited evidence in BCa.

PATIENT & METHODS

A tissue microarray (TMA) of 105 patients with stage IV (pT4b or N1/2) or metastatic BCa who had stable disease after chemotherapy was stained for INPP4B. All patients did not have radical treatment. Light microscopy was used to examine TMA cores. Primary end point was overall survival (OS).

RESULTS

Median follow-up was 17.4 months (range: 1.4-45.5, IQR: 7.1-20.1). INPP4B was positive in 56 patients (66.7%) while 28 patients (33.3%) had low/ negative INPP4B expression. INPP4B negative patients were significantly associated with shorter OS (HR: 1.97, 95% CI: 1.09- 3.57; p=0.022).

CONCLUSION

Loss of INPP4B was associated with shorter OS in BCa patients with stage IV or metastatic disease. Further work is needed to determine if INPP4B is a prognostic marker for response to chemotherapy.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies